Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


WHO Kick-Starts Pilot For Prequalification Of Biologics/Biosimilars

Executive Summary

Manufacturers are being invited to submit expressions of interest in relation to two anticancer monoclonal antibodies on the WHO's essential list of medicines.

You may also be interested in...

WHO Finalizing Guidance For Launch Of Biosimilar Prequalification Pilot

The WHO’s prequalification pilot for biosimilars is to start next month in an effort to make some of the most expensive cancer drugs more widely available to patients in low- and middle-income countries.

WHO Moves Into Prequalification Of Biosimilars; Two Anticancers First In Line

The World Health Organization is to pilot the prequalification of biosimilars in a bid to make expensive cancer treatments more widely available to patients. Ritixumab and trastuzumab will be first in line. The EU generics and biosimilars industry has welcomed the initiative, saying the introduction of biosimilars in the field of oncology could lead to significant changes to standards of care for patients.

Evusheld: UK Urged To Use RWD To Give Clinically Vulnerable Early Access To COVID-19 Treatment

A full appraisal by the UK cost watchdog is not the only way to gauge the safety and effectiveness of Evusheld, argues the independent Drug Safety Research Unit in response to the government’s decision not to buy the licensed COVID-19 drug because of insufficient data on protection. 


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts